Corvus Pharmaceuticals Expands Soquelitinib Trials into Hidradenitis Suppurativa
Event summary
- Corvus Pharmaceuticals initiated a Phase 1b trial of soquelitinib for hidradenitis suppurativa, enrolling up to 25 patients.
- The trial will evaluate safety, tolerability, and efficacy over 12 weeks with a 90-day follow-up.
- Soquelitinib is also in Phase 3 trials for PTCL, Phase 2 for atopic dermatitis, and planned Phase 2 for asthma.
- Hidradenitis suppurativa is driven by Th17 cells, which soquelitinib aims to modulate.
The big picture
Corvus Pharmaceuticals is broadening the potential of its lead candidate, soquelitinib, beyond oncology into autoimmune and inflammatory diseases. The Phase 1b trial for hidradenitis suppurativa marks the company's fourth indication for the drug, following trials in PTCL, atopic dermatitis, and planned studies in asthma. This strategic shift reflects a growing trend in biopharma to repurpose therapies across disease areas, leveraging shared immune pathways.
What we're watching
- Therapeutic Expansion
- Whether soquelitinib's success in Th2-driven diseases translates to Th17-driven hidradenitis suppurativa.
- Clinical Execution
- The pace at which Corvus can enroll patients and generate meaningful efficacy data in this trial.
- Pipeline Diversification
- How Corvus balances multiple indications for soquelitinib, including upcoming asthma trials.
Related topics